Anti-suicidal effect of lithium: Current state of research and its clinical implications for the long-term treatment of affective disorders;Suizidprophylaktische Wirkung von Lithium: Aktueller Forschungsstand und Implikationen für die Therapie affektiver Störungen

Nervenarzt

Volumn 84, Issue 3, 2013, Pages 294-306

  Lewitzka, U ^a,b   Bauer, M ^a   Felber, W ^a   Muller Oerlinghausen B ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DALHOUSIE UNIVERSITY   (Canada)

^c NONE

Author keywords

Affective disorders; Lithium; Prevention; Suicide; Therapy

Indexed keywords

LITHIUM;

ARTICLE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; MOOD DISORDER; MORBIDITY; MORTALITY; PSYCHIATRY; SUICIDAL BEHAVIOR;

ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; LITHIUM COMPOUNDS; LONGITUDINAL STUDIES; MOOD DISORDERS; SUICIDE; TREATMENT OUTCOME;

EID: 84879837427     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-012-3542-5     Document Type: Article

References (75)

1. Emcke C, Uchatius W (2010) Der Schatz im Salzsee. Die Zeit 20.5.2010
2. Bauer M, Grof P, Müller-Oerlinghausen B (Hrsg) (2006) Lithium in Neuropsychiatry.,Informa healthcare, UK
3. World Health Organisation (2011) http://www.who.int/mental-health/ prevention/en/
4. Cavanagh JU, Carson AJ, Sharpe M et al (2003) Psychological autopsy studies of suicide: a systematic review. Psychol Med 33:395-405
5. Nock MK, Borges G, Bromet EJ et al (2008) Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry 192:98-105
6. American Foundation for Suicide Prevention (2011) http://www.afsp.org/ index.cfm?fuseaction = home.viewPage&page-id = 0512CA68-B182-FBB3- 2E4CB905983C0AB8
7. Wolfersdorf M (2008) Suizidalität. Nervenarzt 79:1319-1336
8. Müller-Oerlinghausen B (2003) How should findings on antisuicidal effects of lithium be integrated into practical treatment decisions? Eur Arch Psychiatry Clin Neurosci 253:126-131
9. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV) et al (Hrsg) (2011) Nationale Versorgungsleitlinie Unipolare Depression, Reihe: Interdisziplinäre S3-Praxisleitlinien, Bd 0, 1. Aufl.
10. Lam RW, Kennedy SH, Grigoriadis S et al (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacopsychiatry. J Affect Disord 117:26-43
11. Lohse MJ, Müller-Oerlinghausen B (2010) Psychopharmaka. In: Schwabe U, Paffrath D (Hrsg) Arzneiverodnungs-Report 2010. Springer, Berlin
12. Cipriani A, Pretty H, Hawton K, Geddes JR (2005) Lithium in the prevention of suicidale behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162:1805-1819
13. Lauterbach E, Felber W, Müller-Oerlinghausen B et al (2008) Adjunctive lithium treatment in the prevention of suicidal behavior in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand 118:469-479
14. Barraclough B (1972) Suicide prevention, recurrent affective disorder and lithium. Br J Psychiatry 121:391-392
15. Fieve RR (1977) Stimmungsschaukel. Lithium - die dritte Revolution in der Psychiatrie. Droemer Knaur, München
16. Hanuš H, Zaletalek M (1984) Suicidal activity of patients with affective disorders in the course of lithium prophylaxis. Cesk Psychiatr 80:97-100
17. Coppen A, Standisch-Barry H, Bailey J et al (1991) Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 23:1-7
18. Müller-Oerlinghausen B, Ahrens B, Grof E et al (1992) The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 863:218-222
19. Ahrens B, Müller-Oerlinghausen B, Schou M (1995) Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium- prophylaxis. J Affect Disord 332:67-75
20. Müller-Oerlinghausen B, Müser-Causemann B, Volk J (1992) Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 254:261-270
21. Felber W, Kyber A (1994) Suizide und Parasuizide während und außerhalb einer Lithiumprophylaxe. In: Müller-Oerlinghausen B, Berghörer A (Hrsg) Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Georg Thieme, Stuttgart, S 53-59
22. Nilsson A (1995) Mortality in recurrent mood disorders during periods on and off lithium. A complete population study in 362 patients. Pharmacopsychiatry 281:8-13
23. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W et al (1996) Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 293:103-107
24. Greil W, Ludwig-Mayerhofer W, Erazo N et al (1997) Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 432:151-161
25. Wolf T, Müller-Oerlinghausen B, Ahrens B et al (1996) How to interpret findings on mortality of long-term lithium treated manic-depressive patients? Critique of different methodological approaches. J Affect Disord 39:127-132
26. Tondo L, Jamison KR, Baldessarini RJ (1997) Effect of lithium maintenance on suicidal behaviour in major mood disorders. Ann N Y Acad Sci 29:339-351
27. Baldessarini RJ, Tondo L, Hennen J (1999) Effects of lithium treatment and its discontinuation on suicidal behaviour in bipolar manic-depressive disorders. J Clin Psychiatry 60:77-84, discussion 111-116
28. Bocchetta A, Ardau R, Burrai C et al (1998) Suicidal behaviour on and off lithium prophylaxis in a group of patients with prior suicide attempts. J Clin Psychopharmacol 18:384-389
29. Kallner G, Lindelius R, Petterson U et al (2000) Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 33:18-13
30. Fülle M, Felber W, Israel M (2001) Untersuchung zur Medikation im Vorfeld psychiatrischer Kliniksuizide. 3. Mitteldeutsche Psychiatrietage "Stand der Ursachen- und Therapieforschung bei psychischen Erkrankungen", Magdeburg 16.-17.03. Abstract-Bd, S 14
31. Conell J, Just R, Felber W (2001) Suizidale Handlungen in einer Kohorte 20-jähriger Lithiumbehandlungen. 3. Mitteldeutsche Psychiatrietage "Stand der Ursachen- und Therapieforschung bei psychischen Erkrankungen", Magdeburg 16.-17.03. Abstract-Bd, S 17
32. Ahrens B, Müller-Oerlinghausen B (2001) Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 34:132-136
33. Goodwin FK, Fireman B, Simon GE et al (2003) Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 17:1467-1473
34. Kessing LV, Søndergård L, Kvist K et al (2005) Suicide risk in patients treated with lithium. Arch Gen Psychiatry 62:860-866
35. Bocchetta A (2005) Mortality follow-up of patients since commencing lithium therapy. J Clin Psychopharmacol 25:197-199
36. Angst J, Angst F, Gerber-Werder R et al (2005) Suicide in 406 mood-disorder patients with and without long-term medication: a 40-44 years follow-up. Arch Suicide Res 9:279-300
37. Gonzalez-Pinto A, Mosquera F, Alonso M et al (2006) Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 8:618-624
38. Baldessarini RJ, Tondo L, Davis P et al (2006) Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 8:625-639
39. Guzzetta F, Tondo L, Centorrino F et al (2007) Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 68:380-383
40. Collins JC, McFarland BH (2008) Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. J Affect Disord 107:23-28
41. Keks NA, Hill C, Sundram S et al (2009) Evaluation of treatment in 35 cases of bipolar suicide. Aust N Z J Psychiatry 43:503-508
42. Neuner T, Hübner-Liebermann B, Haen E et al (2011) Completed suicides in 47 hospitals in Germany - Results from the AGATE-study. Pharmacopsychiatry (in press)
43. Kapusta ND, Mossaheb N, Etzersdorfer E et al. (2011) Lithium in drinking water and suicide mortality. Br J Psychiatry 198:346-350
44. Ohgami H, Terao T, Shiotsuki I et al. (2009) Lithium levels in drinking water and risk of suicide. Br J Psychiatry 194:464-465
45. Vestergaard P, Aargaard J (1991) Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 21:33-38
46. Brodersen A, Licht RW, Vestergaard P et al (2000) Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry 176:429-433
47. Coryell W, Arndt S, Turvey C et al (2001) Lithium and suicidal behaviour in major affective disorder: a case-control study. Acta Psychiatr Scand 104:193-197
48. Oquendo MA, Galfalvy HC, Currier D et al (2011) Treatment of suicide attempters with bipolar disorders: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry 168(10):1050-6
49. Mühlbauer HD, Müller-Oerlinghausen B (1985) Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: further evidence for a central serotonergic action of lithium in man. J Neural Transm 61:91-94
50. Price LH, Charney DS, Delgado PL et al (1989) Lithium treatment and serotonergic function. Neuroendocrine and behavioural response to intravenous tryptophan in affective disorder. Arch Gen Psychiatry 46:13-19
51. Wickham EA, Reed JV (1987) Lithium for the control of aggressive and self-mutilating behaviour. Int Clin Psychopharmacol 2:181-190
52. Sheard MH, Marini JL, Bridges CI et al (1976) The effect of lithium on impulsive aggressive behaviour in man. Am J Psychiatry 133:1409-1413
53. Nelson RJ, Chiavegatto S (2001) Molecular basis of aggression. Trends Neurosci 24:713-719
54. Ernst CL, Goldberg JF (2004) Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 12:14-41
55. Meltzer HY (1984) Serotonergic function in the affective disorders: the effect of antidepressants and lithium on the 5-hydroxytryptophan-induced increased in serum cortisol. Ann N Y Acad Sci 430:115-37
56. McCance SL, Cohen PR, Cowen PJ (1989) Lithium increases 5-HT-mediated prolactin release. Psychopharmacology (Berl) 99:276-81
57. Corrodi H, Fuxe K, Hökfelt T et al (1967) The effect of lithium on cerebral monoamine neurons. Psychopharmacologia 11:345-353
58. Ferrie L, Young AH, McQuade R (2006) Effect of lithium and lithium withdrawal on potassium-evoked dopamine release and tyrosine hydroxylase expression in the rat. Int J Neuropsychopharmacol 9:729-735
59. Jope RS, Williams MB (1994) Lithium and brain signal transduction systems. Biochem Pharmacol 47:429-41
60. Ellis J, Lenox RH (1990) Chronic lithium treatment prevents atropine-induced supersensitivity of the murcarinic phophoinositide response in rat hippocampus. Biol Psychiatry 28:609-19
61. Meltzer HY (2005) Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. J Clin Psychiatry 66:530-3
62. Motohashi N (1992) GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Prog Neuropsychopharmacol Biol Psychiatry 16:571-9
63. Dixon JF, Hokin LE (1998) Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA 95:8363-8
64. Kovacsics CE, Gottesman II, Gould TD (2009) Lithium's antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol 49:175-198
65. Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93:8455-8459
66. Gould TD (2006) Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications. Expert Opin Ther Targets 10:377-392
67. Brunello N, Tascedda F (2003) Cellular mechanism and second messengers: relevance to the psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol 6:181-189
68. Kropf D (1980) Probleme und Konzepte psychologischer Lithiumforschung. Pharmacopsychiatr Neuropsychopharmacol 13:168-174
69. Kropf D, Müller-Oerlinghausen B (1979) Changes in learning, memory and mood during lithium treatment. Approach to a research strategy. Acta Psychiatr Scand 59:97-124
70. Johnson FN (1984) The psychopharmacology of lithium. Palgrave Macmillan, London
71. Mann JJ, Waternaux C, Haas GL et al (1999) Toward a clinical model of suicidal behaviour. Am J Psychiatry 156:181-189
72. Khan A, Khan SR, Hobus J et al (2011) Differential pattern of response in mood symptoms and suicide risk measures in severly ill depressed patients assigned to citalopram with placebo or citalopram combined with lithim: role of lithium levels. J Psychiatr Res 45(11):1489-96
73. Coric V, Stock EG, Pultz J et al (2009) Sheehan Suicidality Tracking Scale (Sheehan-STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry (Edgmont) 6:26-31
74. Bschor T, Lewitzka U, Pfennig A et al (2007) Twenty-five years of lithium augmentation. Nervenarzt 78:1237-1247
75. Berghöfer A, Bauer M, Müller-Oerlinghausen B (2002) Antisuicidal effect of lithium as a criterion for the selection of appropriate long-term medication in bipolar patients. In: Kaschka WP (Hrsg) Perspectives in affective disorders. Advanced Biological Psychiatry, Bd 21. Karger, Basel, S 1-9